Chronic myeloid leukemia (CML) is an uncommon malignancy, the treatment and prognosis of which have dramatically shifted over the last decade. Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein have changed this once fatal disease into the model of targeted therapy. This article will review the pharmacological and clinical data supporting the use of imatinib and the second-generation TKIs dasatinib and nilotinib, and the novel TKIs bosutinib and ponatinib.
Chronic myeloid leukemia ( CML ) is an uncommon malignancy , the treatment and prognosis of which have dramatically shifted over the last decade . Characterized by a translocation between chromosomes 9 and 22 , known as the Philadelphia chromosome , small - molecule tyrosine kinase inhibitors ( TKIs ) targeted against the oncogenic BCR - ABL fusion protein have changed this once fatal disease into the model of targeted therapy . This article will review the pharmacological and clinical data supporting the use of imatinib and the second - generation TKIs dasatinib and nilotinib , and the novel TKIs bosutinib and ponatinib .
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?
What tyrosine kinase , involved in a Philadelphia- chromosome positive chronic myelogenous leukemia , is the target of Imatinib ( Gleevec ) ?
BCR-ABL
BCR-ABL